acute myocardial infarction

Infusion of bone marrow mononuclear cells in acute myocardial infarction, meta-analysis of all published to date.

Original title:&nbsp;Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials.&nbsp;Reference:&nbsp;de Jong R, Houtgraaf JH, Samiei S, et al. Circ Cardiovasc Interv. 2014;Epub ahead of print. This meta-analysis included 30 randomized studies conducted between July 2002 and September 2013, totalling 2037 patients with acute myocardial infarction. Of the total, 1218<a href="https://solaci.org/en/2014/04/12/n-4404/" title="Read more" >...</a>

Multivessel angioplasty in acute myocardial infarction improves prognosis

Original title:&nbsp;Acute multivessel revascularization improves 1 year outcomes in ST-elevation myocardial infarction. A nationwide study from AMIS plus registry.&nbsp;Reference:&nbsp;Raban Jeger, et al. International journal of Cardiology 2014;172:76-81 &nbsp; The presence of multiple vessel lesions is present in about 50% of patients referred for primary angioplasty. The accepted strategy is to treat the culprit artery even<a href="https://solaci.org/en/2014/03/07/n-4320/" title="Read more" >...</a>

Complete revascularization in acute myocardial infarction. 1 culprit lesion , then all the others

Original title:&nbsp;Randomized Trial of Preventive Angioplasty in Myocardial Infarction (PRAMI trial).&nbsp;Referencia:&nbsp;David S. Wald et al. N Engl J Med 2013.DOI: 10.1056/NEJMoa1305520. Patients developing ST segment elevation myocardial infarction are effectively treated with primary angioplasty to responsible artery . It is unclear whether revascularized other significant lesions in other non culprit vessels &nbsp;will prevent future events<a href="https://solaci.org/en/2013/09/09/n-3585/" title="Read more" >...</a>

Improved efficacy and also increased bleeding with Rivaroxaban in Acute Myocardial Infarction

Original title:&nbsp;Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction. Results From the ATLAS ACS-2&ndash;TIMI-51 Trial. Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome Thrombolysis In Myocardial Infarction-51.&nbsp;Reference:&nbsp;Jessica L. Mega et al. J Am Coll Cardiol 2013;61:1853&ndash;9. Morbidity and mortality rates following AMI have progressively<a href="https://solaci.org/en/2013/05/07/n-2703/" title="Read more" >...</a>

Prasugrel is not as effective as Ticagrelor in acute myocardial infarction. 

Original title:&nbsp;Comparison of Prasugrel and Ticagrelor loading doses in STEMI patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI Study.&nbsp;Reference:&nbsp;Guido Parodi et al. J Am Coll Cardiol 2013. Article in press. Current guidelines recommend the use of prasugrel or ticagrelor in patients with ST elevation acute coronary syndromes who are due to receive<a href="https://solaci.org/en/2013/04/01/n-2787/" title="Read more" >...</a>

Women have a higher mortality rate in ST-segment elevation acute myocardial infarction 

Original title:&nbsp;Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent?: Gender difference in STMI stratified on age&nbsp;Reference:&nbsp;Amber M Otten et, al.European Heart Journal Acute Cardiovascular Care January 31:1-8 Numerous publications have shown that women have worse outcomes than men in chronic ischemic heart disease but their evolution<a href="https://solaci.org/en/2013/03/13/n-2962/" title="Read more" >...</a>

Renal failure in acute myocardial infarction

Reference:&nbsp;Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as<a href="https://solaci.org/en/2012/09/01/n-3949/" title="Read more" >...</a>

ACC 2024

ACC 2024 | REDUCE AMI: Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

Most clinical trials have shown benefits of beta blockers after acute myocardial infraction, including patients with extensive AMI, and these were carried out in the era before AMI was diagnosed with biomarkers and prior to treatment with coronary angioplasty, use of antithrombotic agents and high intensity statins, and angiotensin-aldosterone system inhibitors. The aim of this<a href="https://solaci.org/en/2024/04/16/acc-2024-reduce-ami-beta-blockers-after-myocardial-infarction-and-preserved-ejection-fraction/" title="Read more" >...</a>

AHA 2023

AHA 2023 | MINT: Liberal vs Restrictive Transfusion in Patients with Acute Coronary Syndrome

The aim of this study was to assess hard end points such as death or MI in patients with acute coronary syndrome (ACS) presenting hemoglobin levels lower than 10 mg/dl. It was a randomized multicenter double blind trial including 3506 participants. The study looked at different transfusion strategies, comparing restrictive strategy with 7-8 g/dl hemoglobin<a href="https://solaci.org/en/2023/11/16/aha-2023-mint-liberal-vs-restrictive-transfusion-in-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>

ESC 2023

ESC 2023 | FIRE-Trial: Physiology Guided Complete Revascularization Benefits Elderly Patients with Myocardial Infarction

Patients over 75 with acute coronary syndrome (ACS) are often badly represented in most significant studies.&nbsp; In this context, the FIRE study looked to determine whether physiology guided complete revascularization is superior to culprit-only revascularization in elderly patients with multivessel disease suffering acute MI.&nbsp; The study included SCA patients over 75, hospitalized for both STEMI<a href="https://solaci.org/en/2023/08/29/esc-2023-fire-trial-physiology-guided-complete-revascularization-benefits-elderly-patients-with-myocardial-infarction/" title="Read more" >...</a>

Top